Literature DB >> 18481130

Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein.

Thomas P Beyer1, Yanqun Chen, Regina K Porter, Deshun Lu, Robert J Schmidt, Nathan B Mantlo, Robert J Konrad, Guoqing Cao.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARalpha) belongs to the nuclear receptor superfamily that regulates multiple target genes involved in lipid metabolism. Cholesterol ester transfer protein (CETP) is a secreted glycoprotein that modifies high-density lipoprotein (HDL) particles. In humans, plasma CETP activity is inversely correlated with HDL cholesterol levels. We report here that PPARalpha agonists increase CETP mRNA, protein and accordingly its activity. In a human CETP transgenic animal model harboring the natural flanking regions (Jiang et al. in J Clin Investigat 90:1290-1295, 1992), both fenofibrate and a specific synthetic PPARalpha agonist LY970 elevated human CETP mRNA in liver, serum protein and CETP activity. In hamsters, the endogenous liver CETP mRNA level and the serum CETP activity were dose-dependently upregulated by fenofibrate. In addition Wy14643, a PPARalpha agonist, also significantly elevated CETP mRNA and activity. In a carcinoma cell line of hepatic origin, HepG2 cells, overexpression of PPARalpha resulted in increased CETP mRNA and agonist treatment further elevated CETP mRNA levels. We conclude that PPARalpha agonists upregulate CETP expression and activity and may play an important role in PPARalpha (agonist mediated HDL cholesterol homeostasis in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481130     DOI: 10.1007/s11745-008-3187-0

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.646


  33 in total

Review 1.  1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis.

Authors:  A R Tall; X c Jiang; Y Luo; D Silver
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Daniel C Howey; Ellen McErlean; Ming-Dauh Wang; Elisa V Gomez; John M Russo
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

3.  Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.

Authors:  B Föger; M Chase; M J Amar; B L Vaisman; R D Shamburek; B Paigen; J Fruchart-Najib; J A Paiz; C A Koch; R F Hoyt; H B Brewer; S Santamarina-Fojo
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

4.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Authors:  Margaret E Brousseau; Ernst J Schaefer; Megan L Wolfe; LeAnne T Bloedon; Andres G Digenio; Ronald W Clark; James P Mancuso; Daniel J Rader
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

5.  Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Authors:  Ronald W Clark; Tamara A Sutfin; Roger B Ruggeri; Ann T Willauer; Eliot D Sugarman; George Magnus-Aryitey; Patricia G Cosgrove; Thomas M Sand; Ronald T Wester; John A Williams; Michael E Perlman; Mark J Bamberger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-22       Impact factor: 8.311

Review 6.  Mechanism of action of fibrates on lipid and lipoprotein metabolism.

Authors:  B Staels; J Dallongeville; J Auwerx; K Schoonjans; E Leitersdorf; J C Fruchart
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

7.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences.

Authors:  X C Jiang; L B Agellon; A Walsh; J L Breslow; A Tall
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 8.  PPAR delta: a dagger in the heart of the metabolic syndrome.

Authors:  Grant D Barish; Vihang A Narkar; Ronald M Evans
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

9.  Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.

Authors:  Ngoc Vu-Dac; Philippe Gervois; Heidi Jakel; Maxime Nowak; Eric Bauge; Helene Dehondt; Bart Staels; Len A Pennacchio; Edward M Rubin; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  J Biol Chem       Date:  2003-03-12       Impact factor: 5.157

10.  Phospholipid transfer protein is regulated by liver X receptors in vivo.

Authors:  Guoqing Cao; Thomas P Beyer; Xiao Ping Yang; Robert J Schmidt; Youyan Zhang; William R Bensch; Raymond F Kauffman; Hong Gao; Timothy P Ryan; Yu Liang; Patrick I Eacho; Xian-Cheng Jiang
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

View more
  2 in total

1.  Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.

Authors:  Michael L Cunningham; Bradley J Collins; Milton R Hejtmancik; Ronald A Herbert; Gregory S Travlos; Molly K Vallant; Matthew D Stout
Journal:  PPAR Res       Date:  2010-10-04       Impact factor: 4.964

2.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.